NCT04379518 2026-01-13
Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients
Roswell Park Cancer Institute
Phase 1/2 Terminated
Clinical Trials
13 trialsNCT03547154 2019-08-12
C98026
Merck Sharp & Dohme LLC
Phase 2/3 Terminated
NCT00038376 2018-10-29
Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02185261 2018-06-07
Interferon α for the Therapy of Minimal Residual Disease
Peking University People's Hospital
Phase NA Unknown
NCT00854581 2018-04-17
Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma
University of Miami
Phase 4 Terminated
NCT02829775 2017-01-09
A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies
Hoffmann-La Roche
Phase 2/3 Completed
NCT02568241 2016-09-29
IDPR-HSCT
Peking University People's Hospital
Phase 1/2 Unknown
NCT00050531 2016-05-11
High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00002621 2014-07-24
Interferon Alfa in Treating Children With HIV-Related Cancer
Children's Oncology Group
Phase 2 Completed
NCT00962715 2012-08-03
Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT00003239 2012-07-30
Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00001567 2008-03-04
A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00483132 2007-06-06
Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III
French Innovative Leukemia Organisation
Phase 3 Completed